- UBS lifts its price targets on Thermo Fisher (TMO +0.3%) and Agilent (A +0.5%) to $127 (from $107) and to $65 (from $57), respectively.
- Analyst Daniel Arias likes the "financial merits of [the TMO] LIFE deal (est 20% accretion in 2014) and TMO's competitive position going forward." New target is 18X forward estimates.
- As for A, the company "should benefit from the gradual macro improvement [while] enthusiasm for the spinoff of EMG appears high, as units comprising the new A performed well in Q4 and appear to be taking share."
UBS sees upside for Thermo Fisher, Agilent
Jan 10 2014, 14:31 ET